# UFP Technologies, Inc. (UFPT)

> Source: Nexqual · https://nexqual.com/UFPT · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, UFP Technologies, Inc. (UFPT), nexqual.com/UFPT" · informational, not investment advice.

**Price:** USD 297.33 (+2.49% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 290.11 · day 290.17–297.72 · 52w 173.86–338.71 · market cap $2.30B · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $632M, net income $72.3M (11.4% margin) (SEC filings).
- Valuation: P/E 31.9x (avg 29.1x at the last 3 fiscal year-ends), EV/EBITDA 21.7x, net debt $108M.
- Insider open-market sales, last ~7 months: 9 Form 4 filings, $13.6M; 9 not under a Rule 10b5-1 plan ($13.6M); 3 by opportunistic insiders (3 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.25 on a 1–5 scale) (4 analysts), mean target USD 355 (range 350–360).
- Total return with dividends: 1Y +48.5% vs S&P 500 +14.9%; 5Y +374.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 2.69, revenue estimate $167M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $206M | $354M | $400M | $504M | $603M | $632M |
| Gross profit | $51.1M | $90.3M | $112M | $147M | $170M | — |
| Operating income | $21.2M | $55.4M | $57.7M | $80.9M | $92.3M | $96.3M |
| Net income | $15.9M | $41.8M | $44.9M | $59.0M | $68.3M | $72.3M |
| EPS (diluted) | $2.09 | $5.45 | $5.83 | $7.58 | $8.75 | — |
| Free cash flow | $8.9M | $4.0M | $30.8M | $56.9M | — | — |
| Gross margin | 24.8% | 25.5% | 28.1% | 29.1% | 28.3% | — |
| Operating margin | 10.3% | 15.7% | 14.4% | 16.0% | 15.3% | 15.3% |
| Net margin | 7.7% | 11.8% | 11.2% | 11.7% | 11.3% | 11.4% |
| Revenue growth | +15.0% | +71.5% | +13.1% | +26.1% | +19.5% | — |
| Cash + short-term investments | $11.1M | $4.5M | $5.3M | $13.4M | $20.3M | — |
| Total debt | $75.0M | $55.0M | $32.0M | $189M | $135M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 31.9x · P/S 3.6x · EV/EBITDA 21.7x · EV/Sales 3.8x · P/B 5.0x · Earnings yield 3.14% · Net debt $108M · EV $2.41B
P/E at fiscal year-ends: Dec 2025 25.4x, Dec 2024 32.3x, Dec 2023 29.5x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | Kozin Marc D | Director | 7,000 | $2.1M | 24.9% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18 | Hudson Symeria | Director | 298 | $95K | 24.3% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-08-14 | Hudson Symeria | Director | 1,926 | $625K | 61.1% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-08-13 | Feldmann Cynthia L | Director | 1,000 | $324K | 18.3% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-10 | Bailly R Jeffrey | Executive Chairman | 13,011 | $4.1M | 100% | No | Too little history (no open-market trades in 2025) |
| 2026-08-06…2026-08-07 | Bailly R Jeffrey | Executive Chairman | 15,695 | $5.0M | 54.7% | No | Too little history (no open-market trades in 2025) |
| 2026-08-06 | Holt Jason | Vice President | 1,100 | $349K | 12.3% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-12 | Feldmann Cynthia L | Director | 1,200 | $287K | 18% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-12 | Croteau Daniel C | Director | 2,864 | $635K | 77% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.25 on a 1–5 scale), 4 analysts; mean target USD 355 (low 350, high 360).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +48.5% | +374.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +48.7% | +36.4% |
| Volatility (annualized) | 47.8% | 44.6% |
| Max drawdown | -30.7% (Feb 2026→Apr 2026) | -47.9% (Sep 2024→Mar 2025) |

## Peers (Medical Devices)
AXGN (AxoGen, Inc.) USD 36.68 +0.55% · TMDX (TransMedics Group, Inc.) USD 72.06 -0.47% · INSP (Inspire Medical Systems, Inc.) USD 72.66 +2.24% · ALMR (Alamar Biosciences, Inc.) USD 29.72 -5.50% · NEOG (Neogen Corporation) USD 11.98 +1.61% · ESTA (Establishment Labs Holdings Inc) USD 63.52 +1.99%

## More
Full page: https://nexqual.com/UFPT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Products | $172.5M | 99.2% | +15.5% |
| Engineering services | $1.0M | 0.6% | -34.4% |
| Tooling and Machinery | $448,000 | 0.3% | +48.3% |
| Total revenue | $174.0M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 93.2%, 26.2%, 21%, 6.8% of revenue from unnamed direct customers (10-Q, filed 2026-08-06).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.69 | $2.73 | -1.6% | $166.9M | 4 |
| Next quarter (ends 2026-12-31) | $2.54 | $2.60 | -2.5% | $162.7M | 4 |
| Current fiscal year (ends 2026-12-31) | $10.62 | $10.34 | +2.7% | $657.8M | 4 |
| Next fiscal year (ends 2027-12-31) | $11.87 | $11.65 | +1.9% | $698.9M | 4 |